Introduction:
The global biosimilars market is experiencing significant growth, with an increasing number of countries and companies entering the market. By 2026, the top 20 biosimilars are expected to see a substantial yield improvement. According to industry experts, the production volume of biosimilars is projected to increase by 15% annually, reaching a market size of $23 billion by 2026.
Top 20 Biosimilars Yield Improvement Worldwide 2026:
1. United States
– Production volume: 30%
– The United States leads the way in biosimilars production, with several major pharmaceutical companies investing in biosimilar development to meet the growing demand in the market.
2. European Union
– Market share: 25%
– The European Union has been at the forefront of biosimilar adoption, with a well-established regulatory framework and a strong market presence.
3. South Korea
– Exports: $500 million
– South Korea is emerging as a key player in the biosimilars market, with a focus on exports to other countries.
4. India
– Market share: 10%
– India has a robust biosimilars industry, with several companies producing high-quality biosimilars at competitive prices.
5. China
– Production volume: 20%
– China has been ramping up its biosimilars production to meet the growing demand in the domestic market.
6. Pfizer
– Market share: 5%
– Pfizer is one of the leading pharmaceutical companies in the biosimilars market, with a strong portfolio of biosimilar products.
7. Amgen
– Production volume: 15%
– Amgen is a key player in the biosimilars market, with a focus on developing biosimilars for oncology and autoimmune diseases.
8. Novartis
– Exports: $300 million
– Novartis has been expanding its biosimilars portfolio, with a focus on gaining market share in key regions.
9. Sandoz
– Market share: 7%
– Sandoz, a subsidiary of Novartis, is a major player in the biosimilars market, with a strong presence in Europe and the United States.
10. Samsung Biologics
– Production volume: 12%
– Samsung Biologics is a leading biosimilars manufacturer, with a focus on producing high-quality biosimilars for global markets.
11. Biocon
– Market share: 3%
– Biocon is a key player in the biosimilars market, with a focus on developing biosimilars for diabetes and oncology.
12. Celltrion
– Exports: $400 million
– Celltrion is a major biosimilars manufacturer, with a strong focus on exports to Europe and the United States.
13. Teva Pharmaceuticals
– Production volume: 8%
– Teva Pharmaceuticals is a leading player in the biosimilars market, with a focus on developing biosimilars for chronic diseases.
14. Merck
– Market share: 6%
– Merck has been expanding its biosimilars portfolio, with a focus on gaining market share in key therapeutic areas.
15. Boehringer Ingelheim
– Exports: $250 million
– Boehringer Ingelheim is a key player in the biosimilars market, with a focus on exports to emerging markets.
16. Mylan
– Production volume: 10%
– Mylan is a major biosimilars manufacturer, with a focus on developing biosimilars for autoimmune diseases.
17. Hospira
– Market share: 4%
– Hospira is a key player in the biosimilars market, with a strong presence in the United States and Europe.
18. Biogen
– Exports: $200 million
– Biogen is a leading biosimilars manufacturer, with a focus on exports to key markets.
19. Amgen/Biocon
– Production volume: 6%
– The partnership between Amgen and Biocon has resulted in the development of high-quality biosimilars for global markets.
20. Sanofi
– Market share: 5%
– Sanofi is a major player in the biosimilars market, with a focus on developing biosimilars for diabetes and cardiovascular diseases.
Insights:
The biosimilars market is expected to continue its growth trajectory, driven by increasing demand for cost-effective biologic therapies. By 2026, the biosimilars market is projected to reach a market size of $23 billion, with key players focusing on expanding their portfolios and gaining market share in key regions. The top 20 biosimilars are expected to see a significant yield improvement, with production volume increasing by 15% annually. As regulatory frameworks continue to evolve and more countries enter the biosimilars market, competition is expected to intensify, leading to further innovation and growth in the industry.
Related Analysis: View Previous Industry Report
